Fc-mediated immune effector functions elicited by recombinant and live-attenuated herpes zoster vaccines [0.03%]
重组和减毒带状疱疹疫苗诱发的Fc介导的免疫效应功能
Zhuangzhuang Huang,Pengfei Jin,Hongxing Pan et al.
Zhuangzhuang Huang et al.
Background: The role of Fc-mediated immune responses in protecting against herpes zoster remains poorly understood. This study aimed to evaluate the Fc-mediated immune responses of anti-VZV glycoprotein E antibodies induc...
Cost-effectiveness of a single dose of the adjuvanted RSVPreF3 vaccine for the prevention of respiratory syncytial virus (RSV) among patients with chronic obstructive pulmonary disease in Italy [0.03%]
意大利慢性阻塞性肺疾病患者单剂量RSVPreF3疫苗的成本效益：预防呼吸道合胞病毒（RSV）感染
Anna Puggina,Filippo Rumi,Eleftherios Zarkadoulas et al.
Anna Puggina et al.
Background: Chronic obstructive pulmonary disease (COPD) increases the risk of severe respiratory syncytial virus (RSV)-related disease. This analysis evaluated the potential public health impact and cost-effectiveness of...
Adherence and efficacy of the 0 - 7 - 21-day versus the 0 - 1 - 6-month hepatitis B vaccination schedules among people who use drugs: a two-year randomized controlled trial [0.03%]
海洛因成瘾者中0-7-21天程序与0-1-6月程序的乙型肝炎疫苗接种依从性和效力的两年随机对照试验比较研究
Xianbin Hou,Ning Li,Hailan Zhang et al.
Xianbin Hou et al.
Background: To compare the adherence and efficacy between the 0 - 7 - 21-day and the 0 - 1 - 6-month hepatitis B virous (HBV) vaccination schedules among people who use drugs (PWUD) in China. ...
Vaccines preventing neonatal sepsis: focus on group B Streptococcus, Klebsiella pneumoniae and Escherichia coli to combat rising antimicrobial resistance [0.03%]
预防新生儿败血症的疫苗：重点关注B群链球菌、肺炎克雷伯氏菌和大肠杆菌以应对日益增长的抗菌素耐药性问题
Francesca Micoli,Simona Rondini,Francesco Berlanda Scorza et al.
Francesca Micoli et al.
Introduction: Neonatal sepsis, a systemic infection occurring in infants within their first 28 days of life, is a leading cause of mortality globally. The burden is especially severe in low- and middle-income countries (L...
The health and economic burden of invasive pneumococcal diseases attributable to V116 versus PCV20 serotypes among adults aged ≥18 in Germany [0.03%]
在德国成人(≥18岁)中，归因于11价肺炎球菌结合疫苗和20价肺炎球菌结合疫苗血清型的侵袭性肺炎链球菌疾病的健康和经济负担
Muloongo Simuzingili,Zinan Yi,Marion de Lepper et al.
Muloongo Simuzingili et al.
Background: Significant residual burden of invasive pneumococcal disease is attributable to Streptococcus pneumoniae serotypes not included in any available vaccines in Germany. This study quantified the burden of invasiv...
Cost-effectiveness analysis of the use of PNEU-C-21 in adults aged ≥50 years in Canada [0.03%]
加拿大50岁以上成人使用PNEU-C-21的 cost-effectiveness分析
Peter P Mueller,Marie-Claude Meilleur,Zinan Yi et al.
Peter P Mueller et al.
Background: This study analyzed the health and economic outcomes of the 21-valent pneumococcal conjugate vaccine (PNEU-C-21; CAPVAXIVE®) compared to either PNEU-C-20 or PNEU-P-23. Cohorts in the cost-effectiveness analys...
Comparative Study
Expert review of vaccines. 2026 Dec;25(1):2608811. DOI:10.1080/14760584.2025.2608811 2026
Reply to letter to editor "public health impact and cost-effectiveness of the adjuvanted RSVPreF3 vaccine for respiratory syncytial virus prevention among adults aged 50 years and older in Germany" [0.03%]
关于《RSVPreF3佐剂疫苗在德国50岁以上成人中预防呼吸道合胞病毒的公共卫生影响和成本效益》一文的回信
Maria Waize,Pavo Marijic,Alen Marijam et al.
Maria Waize et al.
Global status of HPV vaccination two decades in: effective, safe and preventing cancer [0.03%]
全球HPV疫苗接种现状：二十余年的成效、安全及癌症预防作用
Julia M L Brotherton,D Scott La Montagne,Paul J N Bloem
Julia M L Brotherton
Introduction: Prophylactic human papillomavirus vaccines have been in use in populations worldwide for nearly 20 years. Much has been learnt in relation to their effectiveness, safety and how best to effectively implement...
Exploring determinants of vaccine hesitancy among healthcare professionals: a systematic literature review [0.03%]
探索医疗专业人员疫苗犹豫不决的影响因素：系统文献回顾
Valeria Gabellone,Fabiana Nuccetelli,Elisa Gabrielli et al.
Valeria Gabellone et al.
Introduction: This systematic review aims to assess determinants of vaccine hesitancy (VH) among healthcare professionals, to identify knowledge gaps and inform targeted training programs. ...
A human Lyme disease vaccine: two steps forward on the path to prevention [0.03%]
一种人类莱姆病疫苗：通向预防的道路上迈出的两步进展
Raphael Simon,Erik Lamberth,James H Stark et al.
Raphael Simon et al.
Introduction: Lyme disease is caused by the tick-borne spirochete pathogen Borrelia burgdorferi sensu lato (s.l.). Outer surface protein A (OspA) is expressed by B. burgdorferi s.l. while in the tick and antibodies agains...